Peripheral Vascular Devices Market Report Suite - United States - 2020-2026 - MedSuite
Throughout this medical market research, iData Research analyzed 67 peripheral vascular companies across the United States and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.
While this MedSuitereport contains all of the US Peripheral Vascular market analysis, each of the market segments is also available as stand-alone MedCorereports. Additionally, this research includes a peripheral vascular procedure volume analysis which can also be purchased as a separate report, MedPro.
US Peripheral Vascular Devices Market Insights
- Procedure Volumes for the US Peripheral Vascular market – MedPro
- Peripheral Vascular Stent Market - MedCore
- Venous Stent Market - MedCore
- PTA Balloon Catheter Market - MedCore
- Drug-Coated Balloon Market - MedCore
- Atherectomy Device Market - MedCore
- Intravascular Lithotripsy Market - MedCore
- Chronic Total Occlusion Device Market - MedCore
- Surgical Graft Market - MedCore
- Stent Graft Market - MedCore
- Embolic Protection Device Market - MedCore
- Peripheral Thrombus Management Device Market- MedCore
- Inferior Vena Cava Filter and Retrieval Device Market- MedCore
- Carotid Shunt Market- MedCore
- Transcarotid Artery Revascularization Market- MedCore
- Diagnostic & Interventional Catheter Market- MedCore
- Introducer Sheath Market- MedCore
- Vascular Closure Device Market- MedCore
- Transcatheter Embolization Device Market- MedCore
- Peripheral IVUS Catheter Market- MedCore
One of the greatest limitations in this market is the pricing pressure that is occurring within the office-based lab (OBL) setting. Although these clinics have led to a significant increase in efficiency, reducing the average time for patients to be within a hospital, these settings are also incredibly price sensitive. It is typical that there is a 30% discount on devices sold to an OBL, relative to a hospital.
The release of the paclitaxel meta-analysis by Katsanos in late 2018 raised serious concern about the late mortality of drug-coated balloons (DCB) and drug-eluting stents (DES). At the start of 2019, the FDA announced that they would reexamine the safety of paclitaxel products in the peripheries. A large movement occurred shortly after, away from paclitaxel devices and towards more traditional devices. Although the FDA released a statement in August 2019 stating that they were not able to identify a late-mortality signal caused by paclitaxel use in the peripheries, hesitancy about the use of these devices remain.
Overall, the U.S. peripheral vascular device market was valued at $7.1 billion in 2019. This is expected to increase over the forecast period at a CAGR of 5.6% to reach $10.4 billion.
The full report suite on the U.S. market for peripheral vascular devices includes peripheral vascular stents, venous stents, percutaneous transluminal angioplasty (PTA) balloon catheters, drug-coated balloons (DCBs), atherectomy devices, intravascular lithotripsy, chronic total occlusion (CTO) devices, surgical grafts, stent grafts, embolic protection devices (EPDs), peripheral thrombus management devices, inferior vena cava filters (IVCFs) and retrieval devices, carotid shunts, transcarotid arterial revascularization (TCAR) flow reversal systems and stents, diagnostic and interventional catheters, diagnostic and interventional guidewires, introducer sheaths, vascular closure devices (VCDs), transcatheter embolization devices and peripheral IVUS catheters. Many of these devices can be used for treating either coronary arterial disease or peripheral arterial disease (PAD). However, only devices used for peripheral procedures are included in this report.